Tani H, Sadahiro T, Yamada Y, Isomi M, Yamakawa H, Fujita R, Abe Y, Akiyama T, Nakano K, Kuze Y, et al. Direct reprogramming improves cardiac function and reverses fibrosis in chronic myocardial infarction. Circulation. 2023;147(3):223–38.

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.

PubMed  Google Scholar 

Chai R, Xue W, Shi S, Zhou Y, Du Y, Li Y, Song Q, Wu H, Hu Y. Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications. Front Cardiovasc Med. 2022;9:870924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez A, Ravassa S, Beaumont J, Lopez B, Diez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol. 2011;58(18):1833–43.

Article  CAS  PubMed  Google Scholar 

Xing J. Venoarterial extracorporeal membrane oxygenation in acute myocardial infarction. Emerg Crit Care Med. 2024;4(1):1–3.

Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

Article  CAS  PubMed  Google Scholar 

Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–70.

Article  CAS  PubMed  Google Scholar 

Girerd N, Zannad F. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: finding the right patients to treat. J Intern Med. 2023;293(5):550–8.

Article  CAS  PubMed  Google Scholar 

Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, Mouton A, Omoto ACM, Hall ME, Li J, et al. Direct cardiac actions of the sodium glucose co‐transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure‐overload heart failure. J Am Heart Assoc. 2021;10(6).

Ni L, Yuan C, Chen G, Zhang C, Wu X: SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1).

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931–44.

Article  CAS  PubMed  Google Scholar 

Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure. J Am Coll Cardiol. 2011;58(5):474–80.

Article  CAS  PubMed  Google Scholar 

Angermann CE, Santos-Gallego CG, Requena-Ibanez JA, Sehner S, Zeller T, Gerhardt LMS, Maack C, Sanz J, Frantz S, Fuster V, et al. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure. Nat Cardiovasc Res. 2023;2(11):1032–43.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Peng D. New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. Int Immunopharmacol. 2023;118: 110072.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Wang B, Zhang J, He D, Zhang Q, Pan C, Yuan Q, Shi Y, Tang H, Xu F, et al. ALDH2 (Aldehyde Dehydrogenase 2) protects against hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2019;39(11):2303–19.

Article  CAS  PubMed  Google Scholar 

Zhang J, Guo Y, Zhao X, Pang J, Pan C, Wang J, Wei S, Yu X, Zhang C, Chen Y, et al. The role of aldehyde dehydrogenase 2 in cardiovascular disease. Nat Rev Cardiol. 2023;20(7):495–509.

Article  PubMed  Google Scholar 

Li W, Yin L, Sun X, Wu J, Dong Z, Hu K, Sun A, Ge J. Alpha-lipoic acid protects against pressure overload-induced heart failure via ALDH2-dependent Nrf1-FUNDC1 signaling. Cell Death Dis. 2020;11(7):599.

Article  PubMed  PubMed Central  Google Scholar 

Guo H, Yu X, Liu Y, Paik DT, Justesen JM, Chandy M, Jahng JWS, Zhang T, Wu W, Rwere F et al: SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med. 2023;15(680):eabp9952.

Rui H, Yu H, Zou D, Chi K, Xu P, Song X, Liu L, Wu X, Wang J, Xue L. Vaspin alleviates pathological cardiac hypertrophy by regulating autophagy-dependent myocardial senescence. Emerg Crit Care Med. 2024;4(1):4–15.

Article  Google Scholar 

Lin K, Yang N, Luo W, Qian J-f, Zhu W-w, Ye S-j, Yuan C-x, Xu D-y, Liang G, Huang W-j, et al. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling. Acta Pharmacol Sin. 2022;43(10):2624–35.

Li X, Wang M, Kalina JO, Preckel B, Hollmann MW, Albrecht M, Zuurbier CJ, Weber NC. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis. Redox Biol. 2024;69: 102979.

Article  CAS  PubMed  Google Scholar 

Costantino S, Paneni F, Mitchell K, Mohammed SA, Hussain S, Gkolfos C, Berrino L, Volpe M, Schwarzwald C, Luscher TF, et al. Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66(Shc). Int J Cardiol. 2018;268:179–86.

Article  PubMed  Google Scholar 

Braunwald E. The war against heart failure: the Lancet lecture. The Lancet. 2015;385(9970):812–24.

Article  Google Scholar 

Catalucci D, Latronico MVG, Ellingsen O, Condorelli G. Physiological myocardial hypertrophy: How and why? FBL. 2008;13(1):312–24.

CAS  Google Scholar 

Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451(7181):919–28.

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.

Article  PubMed  Google Scholar 

Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–9.

Article  CAS  PubMed  Google Scholar 

Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83(1):503–28.

Article  CAS  PubMed  Google Scholar 

Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, et al. Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2. Circulation. 2023;147(3):276–9.

Article  CAS  PubMed  Google Scholar 

van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18(5):294–306.

Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, Santos-Gallego CG, Lala A: SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure. JAMA Network Open. 2024;7(4).

Yang J, Li L, Zheng X, Lu Z, Zhou H. Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway. Biomed Pharmacother. 2023;165: 115125.

Article  CAS  PubMed  Google Scholar 

Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang K, Cui S, Wang J, Xu T, Du H, Yue H, Ye H, Guo J, Zhang J, Li P, et al. Early Progression of abdominal aortic aneurysm is decelerated by improved endothelial barrier function via ALDH2‐LIN28B‐ELK3 signaling. Adv Sci. 2023;10(32).

Zhong S, Li L, Zhang YL, Zhang L, Lu J, Guo S, Liang N, Ge J, Zhu M, Tao Y, et al. Acetaldehyde dehydrogenase 2 interactions with LDLR and AMPK regulate foam cell formation. J Clin Invest. 2019;129(1):252–67.

Article  PubMed  Google Scholar 

Li W, Yin L, Sun X, Wu J, Dong Z, Hu K, Sun A, Ge J. Alpha-lipoic acid protects against pressure overload-induced heart failure via ALDH2-dependent Nrf1-FUNDC1 signaling. Cell Death Dis. 2020;11(7).

Zhang Y, Zou R, Abudureyimu M, Liu Q, Ma J, Xu H, Yu W, Yang J, Jia J, Qian S et al: Mitochondrial aldehyde dehydrogenase rescues against diabetic cardiomyopathy through GSK3β-mediated preservation of mitochondrial integrity and Parkin-mediated mitophagy. J Mol Cell Biol. 2023;15(9).

Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A, Moscarella E, Gragnano F, Salvatore T, Rinaldi L, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11).

Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575.

Article  PubMed  PubMed Central  Google Scholar 

Berger JH, Matsuura TR, Bowman CE, Taing R, Patel J, Lai L, Leone TC, Reagan JD, Haldar SM, Arany Z, et al. SGLT2 inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice. Circ Res. 2024.

Xia H, Zahra A, Jia M, Wang Q, Wang Y, Campbell SL, Wu J. Na(+)/H(+) Exchanger 1, a potential therapeutic drug target for cardiac hypertrophy and heart failure. Pharmaceuticals. 2022;15(7).

Yeves AM, Ennis IL. Na(+)/H(+) exchanger and cardiac hypertrophy. Hipertens Riesgo Vasc. 2020;37(1):22–32.